Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Forecasted to Earn FY2024 Earnings of ($2.79) Per Share

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Equities researchers at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for Day One Biopharmaceuticals in a note issued to investors on Wednesday, April 24th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($2.79) per share for the year, up from their previous estimate of ($2.80). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($2.67) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ FY2025 earnings at ($2.43) EPS, FY2026 earnings at ($1.34) EPS, FY2027 earnings at $0.15 EPS and FY2028 earnings at $1.87 EPS.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07).

Other equities analysts have also recently issued research reports about the stock. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday. Oppenheimer reaffirmed a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. JPMorgan Chase & Co. upped their price target on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a report on Monday, April 22nd. Needham & Company LLC raised their price objective on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Piper Sandler reiterated an “overweight” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $39.33.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ DAWN opened at $14.92 on Friday. The company has a 50-day moving average price of $15.22 and a 200-day moving average price of $13.81. The stock has a market capitalization of $1.30 billion, a P/E ratio of -6.27 and a beta of -1.48. Day One Biopharmaceuticals has a 1 year low of $9.67 and a 1 year high of $17.85.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in DAWN. Vanguard Group Inc. raised its stake in Day One Biopharmaceuticals by 8.1% in the 3rd quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company’s stock valued at $56,807,000 after acquiring an additional 346,090 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Day One Biopharmaceuticals by 38.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 447,138 shares of the company’s stock valued at $5,486,000 after purchasing an additional 125,050 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Day One Biopharmaceuticals by 22.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock valued at $2,703,000 after buying an additional 40,387 shares in the last quarter. TimesSquare Capital Management LLC boosted its holdings in Day One Biopharmaceuticals by 41.8% in the 3rd quarter. TimesSquare Capital Management LLC now owns 1,142,610 shares of the company’s stock worth $14,020,000 after buying an additional 336,910 shares during the period. Finally, Deutsche Bank AG boosted its holdings in Day One Biopharmaceuticals by 5.5% in the 3rd quarter. Deutsche Bank AG now owns 177,137 shares of the company’s stock worth $2,173,000 after buying an additional 9,219 shares during the period. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Insiders Place Their Bets

In other news, insider Samuel C. Blackman sold 2,258 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $34,434.50. Following the completion of the sale, the insider now directly owns 1,244,662 shares of the company’s stock, valued at approximately $18,981,095.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Samuel C. Blackman sold 2,258 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the completion of the transaction, the insider now directly owns 1,244,662 shares of the company’s stock, valued at approximately $18,981,095.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jeremy Bender sold 7,615 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $116,128.75. Following the sale, the chief executive officer now owns 721,813 shares of the company’s stock, valued at approximately $11,007,648.25. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 55,781 shares of company stock valued at $883,160. Insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.